Pulmonary Arteriovenous Fistulae Clinical Presentation

  • Author: Barry A Love, MD; Chief Editor: Steven R Neish, MD, SM   more...
 
Updated: Sep 24, 2010
 

History

Symptoms caused by pulmonary arteriovenous malformations (AVMs) are often insidious, as the arteriovenous malformations slowly enlarge.

Dyspnea, especially with exercise, may develop over many years. In severe cases, dyspnea in the upright position (platypnea) may be present. Visible cyanosis may be present if a significant degree of desaturation is present.

Hemoptysis and rarely massive hemoptysis may occur.

Less common complaints include chest pain, cough, migraine headaches, tinnitus, dizziness, dysarthria, syncope, vertigo, and diplopia. The cause of these symptoms is not entirely clear, but it may be related to hypoxemia, polycythemia, or paradoxical embolization through the pulmonary arteriovenous malformations.

Next

Physical

Murmurs or bruits over the location of the pulmonary arteriovenous malformations are heard in patients with large pulmonary arteriovenous malformations. These murmurs are most audible during inspiration and are called machinery murmurs.

Digital clubbing and cyanosis may be observed.

The phenomenon of orthodeoxia (desaturation with upright position) is characteristic. Because pulmonary arteriovenous malformations are more frequently found in the lower lobes, with upright position, more blood is directed to the lower lobes because of the effects of gravity, exacerbating the degree of shunting. In addition, platypnea (dyspnea with upright position) may also be noted because of the increased degree of cyanosis.

Because most patients with pulmonary arteriovenous malformations also have HHT, the characteristic mucocutaneous telangiectasias are frequently observed in patients with pulmonary arteriovenous malformations. These lesions are papular, slightly rounded, and sharply demarcated from surrounding skin. They have a few dendritic projections that are ruby colored and partially blanche with pressure. The lesions are present on the face, mouth, chest, and upper extremities (see the image below).

Mucosal telangiectasias are shown in a patient witMucosal telangiectasias are shown in a patient with hereditary hemorrhagic telangiectasia (HHT).

Certainly, the finding of mucocutaneous telangiectasias should prompt a workup for HHT and include evaluation for pulmonary arteriovenous malformations.

Previous
Next

Causes

Epidemiology

Great heterogeneity of symptoms is noted among different families and within single large families with HHT. Some families with HHT predominantly have the pulmonary arteriovenous malformations and cerebral arteriovenous malformations; whereas other affected families predominantly have GI mucosal telangiectasis, which lead to GI bleeding and iron-deficiency anemia.

Inheritance

HHT is an autosomal dominant disorder; however, 20% of cases involve no family history of telangiectasia or recurrent bleeding. Penetrance is age related and nearly complete by age 40 years. Although the arteriovenous malformations in HHT are inherited and should be present at birth, they commonly manifest clinically during adult life, after the vessels have been subjected to pressure for several decades.

Associated syndromes

Communication between pulmonary arteries and pulmonary veins has been reported in cases of trauma and in hepatic cirrhosis, schistosomiasis, mitral stenosis, actinomycosis, Fanconi syndrome, and metastatic thyroid carcinoma. Communications between bronchial arteries and pulmonary arteries that cause a left-to-right shunt develop in chronic inflammatory conditions such as bronchiectasis. Most individuals with pulmonary arteriovenous malformations have HHT. The diagnostic criteria for a definite diagnosis of HHT include at least 3 of the following:

  • Recurrent and spontaneous epistaxis
  • Multiple mucocutaneous telangiectases
  • Visceral lesions (eg, GI arteriovenous malformations, pulmonary arteriovenous malformations)
  • First-degree relative with HHT by these criteria

Associated noncardiac conditions

The most frequently reported associated noncardiac conditions are CNS complications, which occur in 30% of patients. Strokes occur in 18% of patients with CNS complications, transient ischemic attacks occur in 37%, brain abscesses occur in 9%, migraine headaches occur in 43%, and seizures occur in 8%. Paradoxic embolism across pulmonary arteriovenous malformations is the most likely mechanism for major noninfectious strokes. Embolism of infected material accounts for solitary or recurrent brain abscesses. These complications most commonly occur when the feeding arteries are larger than 3 mm in diameter. Hemoptysis and hemothorax are other potentially life-threatening complications. Hemoptysis occurs from ruptured pulmonary arteriovenous malformations or endobronchial telangiectasia.

Idiopathic congenital pulmonary arteriovenous malformations

Idiopathic congenital pulmonary arteriovenous malformations are likely to be single. They are less likely to become enlarged, and the are associated with fewer physical findings than other pulmonary arteriovenous malformations. Idiopathic pulmonary arteriovenous malformations are diagnosed by using the same criteria as for other pulmonary arteriovenous malformations. Idiopathic congenital pulmonary arteriovenous malformations are successfully treated with embolotherapy.

Acquired arteriovenous malformations in hepatopulmonary syndrome

Hepatopulmonary syndrome (HPS), increased alveolar-arterial oxygen gradient, and intrapulmonary right-to-left shunting (defined as the triad of liver disease) may occur in as many as 47% of patients with end-stage liver disease. All types of chronic liver disease may give rise to this syndrome. Approximately 80% of affected patients have signs and symptoms of end-stage liver disease before symptoms from pulmonary arteriovenous malformations develop. These patients have dyspnea, platypnea, clubbing, cyanosis, hypoxia, and orthodeoxia. Pulmonary function results indicate normal lung volumes and expiratory flow rates with low diffusing capacity.

In contrasts to patients with HHT, patients with HPS rarely have discrete arteriovenous malformations on chest radiographs. The calculation of the shunt fraction with the use of 100% oxygen, contrast echocardiography, and radionuclide scanning are diagnostic tests for HPS.

Results of HPS management have been disappointing. Liver transplantation may result in the resolution of HPS, and HPS is not a contraindication to liver transplantation. An improvement in HPS-related pulmonary shunting after therapeutic transjugular intrahepatic portosystemic shunting has been described.

Acquired arteriovenous malformations after surgery for congenital cyanotic heart disease: Pulmonary arteriovenous malformations may develop after Glenn or modified Fontan procedures for congenital cyanotic heart disease. Pulmonary arteriovenous malformations are a known late complication of Glenn anastomosis (ie, superior vena cava [SVC] to right pulmonary artery [RPA]), which occur in as many as 25% of cases. The Fontan operation (ie, SVC to right atrium and proximal RPA; hepatic veins to left pulmonary artery) was designed as a surgical repair for congenital tricuspid atresia. Contrast echocardiography and radionuclide shunt studies have been used to diagnose pulmonary arteriovenous malformations, and embolotherapy has been used successfully to occlude the pulmonary arteriovenous malformations in these cases.

Previous
 
 
Contributor Information and Disclosures
Author

Barry A Love, MD  Assistant Professor, Department of Medicine, Division of Cardiology, Assistant Professor, Division Pediatric Cardiology, Pediatrics and Medicine, Division of Pediatric Cardiology, Mount Sinai School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Nao Sasaki  MBBS, Assistant Professor of Clinical Pediatrics, University of Miami, Leonard M. Miller School of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Charles I Berul, MD  Professor of Pediatrics and Integrative Systems Biology, George Washington University School of Medicine; Chief, Division of Cardiology, Children's National Medical Center

Charles I Berul, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, Cardiac Electrophysiology Society, Heart Rhythm Society, Pediatric and Congenital Electrophysiology Society, and Society for Pediatric Research

Disclosure: Johnson & Johnson Consulting fee Consulting

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Alvin J Chin, MD  Professor of Pediatrics, University of Pennsylvania School of Medicine; Attending Physician, Cardiology Division, Children's Hospital of Philadelphia

Alvin J Chin, MD, is a member of the following medical societies: American Association for the Advancement of Science, American Heart Association, and Society for Developmental Biology

Disclosure: Nothing to disclose.

Gilbert Z Herzberg, MD  Assistant Professor, Department of Pediatrics, Section of Pediatric Cardiology, New York Medical College; Consulting Staff, Department of Pediatrics, Sound Shore Medical Center

Gilbert Z Herzberg, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Chief Editor

Steven R Neish, MD, SM  Director of Pediatric Cardiology Fellowship Program, Associate Professor, Department of Pediatrics, Baylor College of Medicine

Steven R Neish, MD, SM is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, and American Heart Association

Disclosure: Nothing to disclose.

References
  1. Ragsdale JA. Hereditary hemorrhagic telangiectasia: from epistaxis to life-threatening GI bleeding. Gastroenterol Nurs. Jul-Aug 2007;30(4):293-9; quiz 300-1. [Medline].

  2. White RI Jr, Lynch-Nyhan A, Terry P, et al. Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy. Radiology. Dec 1988;169(3):663-9. [Medline].

  3. Giordano P, Nigro A, Lenato GM, et al. Screening for children from families with Rendu-Osler-Weber disease: from geneticist to clinician. J Thromb Haemost. Jun 2006;4(6):1237-45. [Medline].

  4. Pierucci P, Murphy J, Henderson KJ, Chyun DA, White RI Jr. New definition and natural history of patients with diffuse pulmonary arteriovenous malformations: twenty-seven-year experience. Chest. Mar 2008;133(3):653-61. [Medline].

  5. Tomasian A, Lell M, Currier J, Rahman J, Krishnam MS. Coronary artery to pulmonary artery fistulae with multiple aneurysms: radiological features on dual-source 64-slice CT angiography. Br J Radiol. Sep 2008;81(969):e218-20. [Medline].

  6. Grosso M, Groppo Marchisio F, Testa F, et al. Pulmonary arteriovenous malformations: percutaneous treatment preserving parenchyma in high-flow fistulae. Radiol Med. Apr 2008;113(3):395-413. [Medline].

  7. Ishikawa Y, Yamanaka K, Nishii T, Fujii K, Rino Y, Maehara T. Video-assisted thoracoscopic surgery for pulmonary arteriovenous malformations: report of five cases. Gen Thorac Cardiovasc Surg. Apr 2008;56(4):187-90. [Medline].

  8. Pollak JS, Saluja S, Thabet A, et al. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol. Jan 2006;17(1):35-44; quiz 45. [Medline].

  9. Bialkowski J, Zabal C, Szkutnik M, et al. Percutaneous interventional closure of large pulmonary arteriovenous fistulas with the amplatzer duct occluder. Am J Cardiol. Jul 1 2005;96(1):127-9. [Medline].

  10. McFaul RC, Tajik AJ, Mair DD, et al. Development of pulmonary arteriovenous shunt after superior vena cava- right pulmonary artery (Glenn) anastomosis. Report of four cases. Circulation. Jan 1977;55(1):212-6. [Medline].

  11. Cloutier A, Ash JM, Smallhorn JF, et al. Abnormal distribution of pulmonary blood flow after the Glenn shunt or Fontan procedure: risk of development of arteriovenous fistulae. Circulation. Sep 1985;72(3):471-9. [Medline].

  12. Laks H, Kaiser GC, Mudd JG, et al. Revascularization of the right coronary artery. Am J Cardiol. Jun 1979;43(6):1109-13. [Medline].

  13. Gomes AS, Benson L, George B, Laks H. Management of pulmonary arteriovenous fistulas after superior vena cava- right pulmonary artery (Glenn) anastomosis. J Thorac Cardiovasc Surg. Apr 1984;87(4):636-9. [Medline].

  14. Allen SW, Whitfield JM, Clarke DR, et al. Pulmonary arteriovenous malformation in the newborn: a familial case. Pediatr Cardiol. Jan 1993;14(1):58-61. [Medline].

  15. Beck A, Dagan T, Matitiau A, Bruckheimer E. Transcatheter closure of pulmonary arteriovenous malformations with Amplatzer devices. Catheter Cardiovasc Interv. Apr 30 2006;67(6):932-937. [Medline].

  16. Borsellino A, Giorlandino C, Malena S, et al. Early neurologic complications of pulmonary arteriovenous malformation in a newborn: an indication for surgical resection. J Pediatr Surg. Feb 2006;41(2):453-5. [Medline].

  17. Chilvers ER, Whyte MK, Jackson JE, et al. Effect of percutaneous transcatheter embolization on pulmonary function, right-to-left shunt, and arterial oxygenation in patients with pulmonary arteriovenous malformations. Am Rev Respir Dis. Aug 1990;142(2):420-5. [Medline].

  18. Dutton JA, Jackson JE, Hughes JM, et al. Pulmonary arteriovenous malformations: results of treatment with coil embolization in 53 patients. AJR Am J Roentgenol. Nov 1995;165(5):1119-25. [Medline].

  19. Faughnan ME, Lui YW, Wirth JA, et al. Diffuse pulmonary arteriovenous malformations: characteristics and prognosis. Chest. Jan 2000;117(1):31-8. [Medline].

  20. Faughnan ME, Thabet A, Mei-Zahav M, et al. Pulmonary arteriovenous malformations in children: outcomes of transcatheter embolotherapy. J Pediatr. Dec 2004;145(6):826-31. [Medline].

  21. Ference BA, Shannon TM, White RI Jr, et al. Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest. Nov 1994;106(5):1387-90. [Medline].

  22. Gallitelli M, Guastamacchia E, Resta F, et al. Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia, and Brain Abscess. Respiration. Jul 21 2005;[Medline].

  23. Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med. Aug 1998;158(2):643-61. [Medline].

  24. Heutink P, Haitjema T, Breedveld GJ, et al. Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J Med Genet. Dec 1994;31(12):933-6. [Medline].

  25. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. Jun 1996;13(2):189-95. [Medline].

  26. Laks H, Williams W, Trusler G, Castaneda A. Subclavian arterioplasty for the ipsilateral subclavian-to-pulmonary artery shunt. Circulation. Aug 1979;60(2 Pt 2):115-9. [Medline].

  27. Lenato GM, Guanti G. Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des. 2006;12(10):1173-93. [Medline].

  28. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. Dec 1994;8(4):345-51. [Medline].

  29. Pooyan P, Shah L, Goli S, et al. Post-traumatic thoracic arteriovenous fistulas. Tenn Med. Apr 2005;98(4):181-3. [Medline].

  30. Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: a clinical analysis. J Med Genet. Aug 1992;29(8):527-30. [Medline].

  31. Puskas JD, Allen MS, Moncure AC, et al. Pulmonary arteriovenous malformations: therapeutic options. Ann Thorac Surg. Aug 1993;56(2):253-7; discussion 257-8. [Medline].

  32. Remy J, Remy-Jardin M, Wattinne L, Deffontaines C. Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment. Radiology. Mar 1992;182(3):809-16. [Medline].

  33. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu- Osler-Weber syndrome). Am J Med Genet. Mar 6 2000;91(1):66-7. [Medline].

  34. Sluiter-Eringa H, Orie NG, Sluiter HJ. Pulmonary arteriovenous fistula. Diagnosis and prognosis in noncomplainant patients. Am Rev Respir Dis. Aug 1969;100(2):177-88. [Medline].

  35. Sperling DC, Cheitlin M, Sullivan RW, Smith A. Pulmonary arteriovenous fistulas with pulmonary hypertension. Chest. Jun 1977;71(6):753-7. [Medline].

  36. Swanson KL, Prakash UB, Stanson AW. Pulmonary arteriovenous fistulas: Mayo Clinic experience, 1982-1997. Mayo Clin Proc. Jul 1999;74(7):671-80. [Medline].

  37. Ueki J, Hughes JM, Peters AM, et al. Oxygen and 99mTc-MAA shunt estimations in patients with pulmonary arteriovenous malformations: effects of changes in posture and lung volume. Thorax. Apr 1994;49(4):327-31. [Medline].

  38. Vase P, Holm M, Arendrup H. Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia. Acta Med Scand. 1985;218(1):105-9. [Medline].

Previous
Next
 
Mucosal telangiectasias are shown in a patient with hereditary hemorrhagic telangiectasia (HHT).
Left lower lobe arteriovenous malformation (AVM).
Lateral radiograph showing a left lower lobe arteriovenous malformation (AVM).
Large left lower lobe arteriovenous malformation (AVM) showing a feeding vessel to the left atrium.
Another view of the infused CT scan of the left lower lobe arteriovenous malformation (AVM).
Pulmonary angiographic findings are required not only to confirm the diagnosis but also to plan therapeutic embolization.
Small arteriovenous malformations (AVMs) in the right and left lower lobes.
Lateral radiograph shows a left lower lobe arteriovenous malformation (AVM).
Contrast-enhanced CT scan showing a left lower lobe arteriovenous malformation (AVM).
Right lower lobe arteriovenous malformation (AVM).
CT scan obtained after coil embolotherapy.
Left lower lobe embolotherapy performed at the same sitting as the coil embolotherapy depicted in the previous image.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.